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Abstract The prevention of systemic viral and bacterial
infections by effective vaccination represents an essential
task of pediatric nephrologists caring for children with
chronic renal failure (CRF) undergoing renal transplan-
tation (RTPL) with life-long immunosuppression. This
review addresses three issues: risk of vaccine-preventable
diseases, safety, immunogenicity, and clinical efficacy of
available vaccines, and implementation of immunization
guidelines. Infections (including vaccine-preventable in-
fections) represent the leading cause of morbidity and
mortality in children on dialysis and after RTPL. Vacci-
nation in children with CRF and after RTPL is safe and
does not cause reactivation of an immune-related renal
disease or rejection after RTPL. Children with CRF gen-
erally produce protective serum antibodies to primary
vaccinations with killed or component vaccines and live
virus vaccines; some children on dialysis and after RTPL
may not respond optimally, requiring repeated vaccina-
tion. Proof of vaccine efficacy is absence of disease,
which can only be confirmed in large cohort studies. A
few observational studies provide evidence that vaccina-
tion has contributed significantly, at least in the western
hemisphere, to the low prevalence of vaccine-preventable
diseases among children with CRF. Close cooperation
between the local pediatrician/practitioner and the pedi-
atric nephrologist is essential for successful implementa-
tion of the vaccination schedule.
Keywords Vaccination · Safety · Immunogenicity ·
Efficacy · Chronic renal failure · Dialysis · Renal
transplantation
Introduction
The prevention of systemic viral and bacterial infections
by effective vaccination represents an essential part of a
pediatrician’s work. This task is particularly important for
those specialists caring for children with chronic renal
failure (CRF) that eventually undergo renal transplanta-
tion (RTPL) with life-long immunosuppression. The fol-
lowing issues will be addressed in children with CRF
on conservative treatment, on long-term dialysis, and af-
ter RTPL: (1) the risk of vaccine-preventable diseases,
(2) the safety, immunogenicity, and clinical efficacy of
available vaccines, and (3) the implementation of the
recommended immunization guidelines.
Immunization recommendations—for healthy and im-
munocompromised children—vary between countries and
possibly even between different health authorities de-
pending on the local population base. Recommendations
for immunization in children with CRF follow the pri-
mary vaccine schedules [1, 2, 3]; in addition, children
with CRF should be protected against varicella, influenza,
hepatitis B, and Streptococcus pneumoniae if not included
in their primary schedule. Specific guidelines and rec-
ommendations for children with CRF have continuously
been updated [4, 5, 6, 7, 8, 9, 10]. Most recommendations
contain a commentary stating that the “guidelines are
derived from small or controversial studies, or represent
the opinion of the group of experts grading the evidence
on level C” [10]. The implementation of these guidelines
varies substantially in different pediatric renal centers
[11].
Children with CRF on conservative treatment or dial-
ysis have no significant immune impairment except in a
few clinical conditions, e.g., nephrotic syndrome and
systemic lupus erythematosus. Some children on perito-
neal dialysis have hypogammaglobulinemia (total IgG or
IgG subclasses) either due to loss of IgG in the dialysate
or due to impaired IgG production [12, 13, 14, 15, 16,
17, 18, 19]. After RTPL, immunosuppressed infants and
young children without specific protection—either after
immunization or wild type infection—are at risk from
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benign childhood infections that can be severe and life
threatening [20, 21].
The risk of vaccine-preventable diseases
Publications from large registries or single centers show
that infections represent the leading cause of morbidity
and mortality in children on dialysis and after RTPL [20,
21, 22, 23, 24, 25, 26]. Most reports are limited and do not
provide precise information regarding the specific pa-
thogens. Thus, epidemiological data on incidence and
prevalence of vaccine-preventable infections in children
with CRF are scarce [21, 27, 28, 29, 30, 31].
Whereas hepatitis B has become very rare in some
western countries due to vaccination [27], it is still highly
prevalent in other areas, affecting up to one-third of dia-
lyzed children [30, 31]. Almost 50% of children under-
going RTPL without a history of wild type infection or
vaccination developed varicella with significant morbid-
ity and mortality, whereas the incidence and severity of
varicella was much lower in the immunized children [21].
In addition, several individual cases highlight the risk of
vaccine-preventable infections. Measles [32, 33, 34], va-
ricella [21, 35], or influenza [36] were responsible for
significant morbidity and mortality after RTPL. Hemo-
philus influenzae type b and Streptococcus pneumoniae
caused peritonitis in children on peritoneal dialysis [27].
A prospective study from our center covering more
than a decade showed a generally low prevalence of
vaccine-preventable diseases [27] based on two observa-
tions: firstly, a low prevalence of these infections among
healthy children (and the patients’ siblings) [37] and
secondly, a high immunization rate producing detectable
serum antibodies. In contrast to this report are the ob-
servations in an era of waning herd immunity where
measles and other infections did not only emerge, but also
presented with non-specific or atypical symptoms and a
severe course [34].
The safety, immunogenicity, and clinical efficacy
of available vaccines
A broad array of vaccines are currently available and
recommended for children with CRF. The majority of
previous reports focused on the safety and short-term
immunogenicity [28, 29, 38, 39, 40, 41, 42, 43, 44, 45, 46,
47, 48, 49, 50, 51, 52, 53, 54, 55], whereas data on the
long-term clinical efficacy are rare [21, 27, 56].
Safety
Vaccination in children with CRF carries two potential
risks, i.e., rejection after RTPL and live vaccine-induced
infectious disease after RPTL. Killed or component vac-
cines have not shown any deleterious effect on renal
function in children on conservative treatment or after
RTPL; in particular, there was no evidence of an in-
creased rate of graft rejection and the efficacy of dialysis
was not affected in children on either peritoneal or he-
modialysis [27, 38, 39, 40, 41, 42, 43, 44, 45, 48, 49, 50,
51, 52, 53, 54, 55].
Live virus vaccines have also been documented as safe
in children on conservative treatment or on dialysis [21,
27, 28, 29, 46, 47, 56]. Most guidelines do not recom-
mend live virus vaccines after RTPL. Two studies, how-
ever, reported live virus vaccination after RTPL: Zamora
et al. [57] immunized 17 children against varicella; only 1
child had mild vaccination varicella and there was no
evidence of graft rejection or impairment of renal func-
tion. Rand et al. [58] vaccinated 18 children after liver
transplantation against measles without any complications
attributable to the vaccine. There is also personal expe-
rience with live vaccines after RTPL, as a few of our
adolescent transplant patients were given a booster vac-
cination against measles, mumps, and rubella on the oc-
casion of “routine” vaccination at school (against our
current recommendations). None of the patients suffered
any adverse effects.
In summary, vaccination in children with CRF and
after RTPL appeared to be safe, apart from local reactions
or a transiently raised temperature, as observed in healthy
children. There is no evidence that vaccination led to
reactivation of an underlying immune-related renal dis-
ease in children with CRF or to rejection in children after
RTPL. In addition, vaccination did not—as sometimes
feared by parents or patients—aggravate CRF, i.e., ac-
celerate decline in renal function. A recent publication on
children with idiopathic nephrotic syndrome (and normal
renal function) apparently showed a risk of relapse after
meningococcal C conjugate vaccination; there was,
however, bias and the conclusion was not clear [59].
Immunogenicity
Children with CRF generally produce detectable and
protective serum antibodies to primary vaccinations with
killed or component vaccines and live virus vaccines, as
listed in Table 1: diphtheria [38, 40], tetanus [38, 40],
pertussis [38], inactivated poliomyelitis [38, 42], hepatitis
B [27, 43, 44, 45], measles [27, 46, 47], varicella [21, 27,
28, 29, 56], influenza [48, 49, 50], Hemophilus influenzae
type b [51, 52], and S. pneumoniae [27, 53, 54, 55]. Also,
administration of boosters after RTPL induced a signifi-
cant antibody response: diphtheria [39, 41] and tetanus
[39, 41].
There are, however, two barriers towards optimal pro-
tection. Firstly, some children on dialysis and after RTPL
may not respond optimally, and not as well as children
on conservative treatment, to primary vaccination, e.g.,
hepatitis B, influenza, and S. pneumoniae, i.e., they pro-
duce lower specific serum antibodies [45, 50, 55]. This
problem could be overcome in some patients by repeated
vaccinations (with increasing dose) [27, 45]. Secondly,
vaccine serum antibodies in children with CRF have a
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tendency to wane over a short period of time, i.e., 6–
12 months [27, 41, 42, 45, 51, 52, 54, 56]. Therefore,
repeated measurement of serum antibodies with appro-
priate revaccination has been recommended [17, 27, 45,
51, 54].
Clinical efficacy
There are several methodological difficulties in the as-
sessment of the clinical efficacy of vaccinations in chil-
dren with CRF. The proof of vaccine efficacy is the ab-
sence of disease, which can only be confirmed in large
cohort studies, but not in individuals. Only a few pro-
spective or observational studies have investigated the
clinical efficacy of specific vaccinations. Broyer et al.
[21] clearly demonstrated the benefit of varicella vacci-
nation prior to RTPL, and this was confirmed by other
studies [27, 29, 56]. Although a few vaccinees developed
varicella after RTPL, the course was mild and renal graft
function was not affected. Hepatitis B has almost “dis-
appeared” in those countries where the vaccine has been
easily available [27].
These observations provide some evidence that the
implementation of various vaccines has contributed sig-
nificantly, at least in the western hemisphere, to the low
prevalence of vaccine-preventable diseases among chil-
dren with CRF. Another explanation for the low preva-
lence among patients is the low prevalence of these in-
fections—with the exception of varicella—among healthy
children (and the patients’ siblings) in the western world
[60]. There is, however, a re-emergence of infections,
e.g., measles, with decreased vaccination rate in the
general populations [34].
There were also apparent vaccination failures. Chil-
dren on peritoneal dialysis developed peritonitis caused
by S. pneumoniae or Hemophilus influenzae type b de-
spite the presence of serum antibody titers [27]. Serum
antibody titers considered to be protective for healthy
children may not prevent infections in children with CRF,
and the concentration of specific antibodies in the peri-
toneal fluid may not be sufficient.
The implementation
of the recommended immunization guidelines
The immunization rate in the general pediatric population
is often moderate, i.e., 80% or less, as reported in healthy
children in the United States [61], Switzerland [60], and
our local community [62]. Some vaccine advisory com-
mittees recommend a reminder/recall (R/R) system by
vaccination providers to increase vaccination rates [63].
The immunization schedule currently recommended at
the University Children’s Hospital Zurich, Switzerland is
given in Table 1. Due to the low prevalence of tubercu-
losis in Switzerland, the Swiss Health authorities do not
recommend BCG vaccine for residents in Switzerland.
Administration of the vaccines
Children with CRF are often looked after by a multidis-
ciplinary team including several physicians (e.g., general
practitioner, pediatrician, nephrologist, urologist). Vacci-
nations might be overlooked as “minor” problems com-
pared with growth, nutrition, dialysis, and social diffi-
culties. In addition, some parents and patients also either
perceive an associated risk of vaccinations—e.g., measles
Table 1 Recommended immunizations in children with chronic renal failure in Zurich, Switzerland (2003) (RTPL renal transplantation)
Vaccination/infection Selection of patients Schedule Remarks
Diphtheria-tetanus-
pertussis (acellular)
All 2, 4, 6, 12–15 months; 5,
10 years
Poliomyelitis (inactivated) All 2, 4, 6, 12–15 months; 5,
10 years
Measles-mumps-rubella All 1st dose at 12 months, 2nd dose
>1 month later
Live virus: if possible prior to RTPL (in
selected patients boosters or even primary
vaccination after RTPL)
Hepatitis A Hepatitis C or liver
disease
2 doses within 6 months
Hepatitis B All 3 doses within 6 months (0, 1, 6) <10 years: 5 mg per dose; >10 years: 10 mg per
dose. 4th or 5th dose (with doubling the dose)
if titer <100 IE/ml
Varicella Negative history of wild-
type infection and nega-
tive IgG
1st dose at 12 months Live virus: if possible prior to RTPL (in
selected patients boosters or even primary
vaccination also after RTPL). 2nd dose if
2 months after 1st vaccination IgG negative
Influenza All on transplant waiting
list and after RTPL
1 annual dose in autumn According to yearly up-to-date recommenda-
tion of Governmental Office of Public Health
Hemophilus influenzae
type b (conjugate)
All 2, 4, 6, 12–15 months; >2 years:
1 dose
In patients >5 years only, if IgG negative
Streptococcus pneumoniae Patients on peritoneal
dialysis or nephrotic-
range proteinuria
<2 years: 2, 4, 6, 12–15 months;
>2 years: 2 doses (0, 2 months)
plus 1 dose of 23-valent
7-valent conjugate vaccine. >2 years: in
addition 23-valent polysaccharide antigen
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and autism/inflammatory bowel disease or hepatitis B and
multiple sclerosis—or fear that vaccinations may aggra-
vate CRF or induce a rejection of the renal graft. We
recently reported a high immunization rate (almost 100%)
in our center based on two factors [27]. Firstly, the renal
team was responsible for the administration and surveil-
lance—at least annually in October on the occasion of the
influenza vaccine—of the vaccination schedule. Second-
ly, the renal team provided repeated information—for
parents, patients, and all involved professionals—on both
the risks of systemic infections on dialysis and after
RTPL, and the potential protection induced by the avail-
able vaccines.
Preventive strategies in children with CRF also com-
prise an extended immunization schedule of their siblings
and household contacts, including not only the standard
primary vaccines, but also varicella, influenza, and S.
pneumoniae. As these family members are vaccinated by
their local physicians (either pediatrician or general prac-
titioner), good communication and documentation are
mandatory.
Running out of time before RTPL
Some children start dialysis at an early age during infancy
or even as neonates. These young children aim for early
RTPL, which is performed in many centers at 2 years of
age or even younger. Therefore, the available time for
administering all the primary vaccines—in particular all
live vaccines—before the introduction of renal replace-
ment therapy, either dialysis or RTPL, may be short. If the
topic of vaccination is introduced early to the parents,
vaccination can be completed by 15–18 months of age. As
the immunogenicity of some vaccines can be impaired
by dialysis, repeated (and time-consuming) vaccinations
might be necessary to induce protective serum antibody
titers. Thus, it might be justified to delay RTPL in indi-
vidual cases for 1–2 months to revaccinate the child.
Vaccination after RTPL
Long-term graft survival has continuously improved in
pediatric recipients [22, 23, 25, 26]. Thus, a substantial
part of the regular immunization schedule, in particular
boosters, will be administered to immunocompromised
children with a functioning graft. These patients—and
their caregivers—require careful information on the po-
tential benefits and risks. Killed or component vaccines
can be administered safely and effectively after RTPL.
Two issues are still unsolved. Firstly, attenuated live
vaccines are contraindicated after RTPL, according to
most guidelines based on the potential risk of inducing
life-threatening infections. The data base, however, is
poor. Only two publications—apart from anecdotal re-
ports—studied live vaccines after solid organ transplan-
tation, either varicella after RTPL [57] or measles after
liver transplantation [58], and reported a safe and effec-
tive administration. However, live virus vaccines in in-
dividual cases after RTLP can only be endorsed when
very specific indications are present where the benefit
significantly outweighs the risk, e.g., in an era of low herd
immunity. Measles represents a special risk as, in contrast
to varicella, no effective treatment is available [34]. There
is doubt that any prospective study on live vaccines after
RTPL would get ethical approval.
Secondly, healthy pediatric vaccinees have a good
immune memory and do not require a booster when the
titer, e.g., of hepatitis B, decreases. Whether this is also
true for children with CRF and after RTPL is not clear.
Repeated measurement of serum antibodies with “ap-
propriate” boosters if titers have declined has been
recommended [17, 27, 45, 51, 54]. The “appropriate”
schedule (annually, biannually?) remains open to debate.
Outlook and future directions
Continuous updating of the vaccination schedule is
mandatory. Since 2001, the inactivated poliomyelitis vac-
cine has replaced the oral vaccine, and the conju-
gate pneumoccocal vaccine has been introduced. Unfor-
tunately, vaccinations against cytomegalovirus, Epstein-
Barr virus (EBV), BK (polyoma) virus, hepatitis C, or
Pneumocystis carinii, causing serious and life-threatening
infections in children with CRF and after RTPL, are not
yet available. There is, however, an ongoing study of an
EBV vaccine in pediatric patients awaiting solid organ
transplantation.
Peritoneal dialysis and hemodialysis cause a disruption
of the cutaneous barrier of infections with subsequent risk
of bacteremia, exit-site infections, or peritonitis, the most
common pathogens being staphylococci (S. aureus or
coagulase-negative staphylococci) [64, 65, 66]. A new
vaccine against S. aureus has emerged. Whereas previous
vaccines consisting of inactivated whole cells or staphy-
lococcus toxoid had been unsuccessful [67, 68], a new
conjugate vaccine conferred at least transient immunity
against S. aureus bacteremia in an adult hemodialysis
population [69].
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